- Home
- ELTX vs MAIA Comparison
ELTX vs MAIA Comparison
Compare ELTX & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELTX
- MAIA
- Stock Information
- Founded
- ELTX 2011
- MAIA 2018
- Country
- ELTX United States
- MAIA United States
- Employees
- ELTX N/A
- MAIA N/A
- Industry
- ELTX Biotechnology: Pharmaceutical Preparations
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- ELTX Health Care
- MAIA Health Care
- Exchange
- ELTX Nasdaq
- MAIA Nasdaq
- Market Cap
- ELTX 121.7M
- MAIA 46.7M
- IPO Year
- ELTX N/A
- MAIA 2022
- Fundamental
- Price
- ELTX $7.84
- MAIA $1.94
- Analyst Decision
- ELTX Strong Buy
- MAIA
- Analyst Count
- ELTX 2
- MAIA 0
- Target Price
- ELTX $9.50
- MAIA N/A
- AVG Volume (30 Days)
- ELTX 54.7K
- MAIA 526.7K
- Earning Date
- ELTX 08-12-2025
- MAIA 08-08-2025
- Dividend Yield
- ELTX N/A
- MAIA N/A
- EPS Growth
- ELTX N/A
- MAIA N/A
- EPS
- ELTX N/A
- MAIA N/A
- Revenue
- ELTX N/A
- MAIA N/A
- Revenue This Year
- ELTX N/A
- MAIA N/A
- Revenue Next Year
- ELTX N/A
- MAIA N/A
- P/E Ratio
- ELTX N/A
- MAIA N/A
- Revenue Growth
- ELTX N/A
- MAIA N/A
- 52 Week Low
- ELTX $3.34
- MAIA $1.40
- 52 Week High
- ELTX $9.99
- MAIA $4.24
- Technical
- Relative Strength Index (RSI)
- ELTX 57.03
- MAIA 61.28
- Support Level
- ELTX $7.70
- MAIA $1.60
- Resistance Level
- ELTX $8.05
- MAIA $1.95
- Average True Range (ATR)
- ELTX 0.32
- MAIA 0.11
- MACD
- ELTX -0.10
- MAIA 0.02
- Stochastic Oscillator
- ELTX 28.92
- MAIA 94.39
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.